Objective:To investigate the expression and clinical significance of Wnt5a and Ror2 in human osteosarcoma tissues.Methods:SP immunohistochemistry was performed to detect the expressions of Wnt5a and Ror2 protein in specimens of 55
osteosarcoma patients and 15 osteochondroma patients. Then the interrelation of the expressions of wnt5a and Ror2 were calculated and
analyzed.Results:The positive rate of both Wnt5a and Ror2 expression showed significant differences between osteosarcoma group and
osteochondroma group (Wnt5a: 74.55%, 20.00%, Ror2: 13.33%, 70.91%, P<0.05), and showed significant differences between
osteosarcoma metastasis group and non-metastasis group (Wnt5a: 100 %, 66.67 %; Ror2: 100 %, 61.90 %, P<0.05). In osteosarcoma
Enneking stage, the expression ofWnt5a in I, Ⅱ and Ⅲ stage was11.11%, 84.38 %, Ⅲ 100.00%, respectively; the expression of Ror2 in
I, Ⅱ and Ⅲ stage was 22.22 %, Ⅱ 72.73 %, 100.00 %, respectively. The positive rate of Wnt5a was similar to Ror2, and both of them
were statistically significant between Enneking stage Ⅰ and Ⅱ, Ⅰ and Ⅲ (P<0.05), but no significance between Enneking stage Ⅱ and
Ⅲ (P>0.05). A positive correlation existed between the expressions of wnt5a and Ror2 (osteosarcoma: r=0.844, P<0.01; osteochondroma:
r=0.808, P<0.01), but the differences of the positive rate of bothWnt5a and Ror2 in osteosarcoma sex, age and pathological type were not
statistically significant (P>0.05).Conclusion:Wnt5a and Ror2 may act as a tumor promoter in osteosarcoma with synergistic effect,
which are positively related to the severity, invasion and metastasis of osteosarcoma. |